Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept Dr. Reddy’s Laboratories Ltd. along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced that the US Food and Drug Administration…
New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung Cancer bioAffinity Technologies, Inc. a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released a new…
BioTalent Canada Launches Training to Help Employers Prevent and Respond to Workplace Sexual Harassment BioTalent Canada is launching online training courses to empower managers and hiring leaders to confidently prevent and address workplace sexual harassment in Canada’s bio-economy. These courses…
Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma Pilatus Biosciences Inc., a biopharmaceutical company developing novel metabolic checkpoint immunotherapies for liver and gastrointestinal cancers, today announced that the U.S. Food and Drug Administration…
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 2026 Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American…
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for…
Korsana Biosciences Emerges from Stealth with $175 Millon in Funding to Advance Potential Best-in-Class Therapeutics for Neurodegenerative Diseases Korsana Biosciences, Inc. a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases, today announced its emergence…
Flashpoint Therapeutics Announces Major Publication on Novel HPV Cancer Vaccine Flashpoint Therapeutics, a biotechnology company pioneering a new class of structural nanomedicines, today announced a major, peer-reviewed publication demonstrating the power of its Spherical Nucleic Acid (SNA) platform in immuno-oncology.…
Twist Bioscience Expands Antibody Discovery Offering with Bispecific Licensing Agreement Twist Bioscience Corporation a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies…
Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program Newron Pharmaceuticals S.p.A. a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that…
Worldwide Clinical Trials Completes Acquisition of Catalyst Clinical Research Worldwide Clinical Trials a global contract research organization (CRO), has completed its acquisition of Catalyst Clinical Research, LCC (“Catalyst”) – a specialized oncology CRO and scalable functional service provider (FSP). This strategic transaction creates a combined organization…
Australian Breast Cancer Innovators Close $27M Private Funding Round OncoRes Medical today announced it has closed an AUD $27M private funding round (‘the Funding round’) to progress clinical development and regulatory milestones for its Quantitative Micro-Elastography (QME) Imaging System, Elora™.…